Supercritical Fluid Chiral Separations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Supercritical Fluid Chiral Separations
The combination of supercritical fluid chromatography with chiral separation media offers several analytival advantages over traditional liquid chromatography techniques.


Pharmaceutical Technology


In progress

Productivity will play a big role in future advances in SFC chiral methods. Much of the problem in progressing the technique stems from the fact that a lot of SCF work so far has been conducted with proprietary compounds and information is not available.

Regis scientists are conducting studies involving different chiral phases from two manufacturers, with one column in a series being used for mixing. "I think the biggest improvements will come in the machinery. Advances in the machinery and feedback from companies will move the technology forward," says Mannerino. "When a manufacturer does research, it a completely different story than when it is done in other settings. We are in constant communication with equipment manufacturers."

As with any chromatographic technique, continued compliance with US Food and Drug Administration regulations is an issue. For this reason, the approval of SFC chiral methods is another important factor in its success. "A validated synthesis will always be favorable over a chromatographic technique, even when it doesn't make sense financially or scientifically,"says Mannerino. Perhaps the greatest obstacle, however, is convincing high-level personnel. "It's just fighting old-school thinking,"he says. have a lot of upper management in companies that didn't grow up with advanced chromatography techniques, and they didn't go to school or internships with it. There are so many variables that you can't explain in chromatography, and so in their eyes it's not a reliable technique. Many organic chemists won't buy into it. It's changing slowly."

This article is based on an interview with Francis Mannerino, director of chromatography at Regis Technologies (Morton Grove, IL).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here